Advancing Biotech and Specialty Pharma Solutions
from Scientific Insight to Real-World Impact
I work across biotechnology, specialty pharmaceuticals, and applied scientific research. Over time, this has led me to build and operate several projects and companies that may appear unrelated on the surface: drug discovery, international pharmaceutical access, and animal health products. In practice, they reflect a consistent approach: identifying unmet needs, applying scientific rigor, and turning ideas into tangible outcomes.
This website is designed to provide clarity for investors, partners, and potential acquirers about what I do, what I am focused on, and how to engage.
Ordered by current priority and time commitment
Capital-efficient platform focused on expanding access to specialty pharmaceuticals outside the U.S. by in-licensing exclusive rights to FDA-approved, high-value therapies and partnering with exclusive distributors in each market.
Currently my main focus. Details available for qualified parties upon request.
Development of an Asparagine Endopeptidase (AEP) inhibitor for Alzheimer's disease. Currently in lead optimization stage with mechanistic and translational work supporting clinical development pathway.
Animal health and nutrition business, maintained with limited day-to-day involvement. Established operational framework supports ongoing activities.
Access to specialty pharmaceuticals remains highly uneven across global markets. Many FDA-approved, high-value therapies—often reformulated and facing limited competition—are unavailable to patients outside the United States. This platform addresses that gap through a capital-efficient, partnership-driven model.
Objective: To accelerate patient access to differentiated therapies in underserved markets worldwide, while capturing strong upside through capital-efficient scaling and exclusive distribution partnerships.
I have published analytical papers focused on forecasting clinical trial outcomes and regulatory decisions for publicly traded biotechnology companies. These analyses were published prior to relevant events and used to inform structured strategies.
Reported summary across published analyses with methodology available for review.
A comprehensive analysis of Cassava Sciences and Simufilam, examining the scientific foundation and clinical trial structure. The assessment assigned a probability of success between 0.00032% to 0.0034%, indicating a high statistical likelihood of failure.
Analysis estimating $5.21 price per share excluding current cash for Milestone Pharmaceuticals if Etripamil received FDA acceptance, with an estimated 80% probability of approval.
Follow-up analysis after MIST received a Complete Response Letter for CMC issues. The CRL addressed chemistry, manufacturing, and control concerns—not safety or efficacy—presenting a favorable risk-to-reward opportunity at approximately $0.80 per share.
Critical analysis of aTyr Pharma's Phase III study for efzofitimod in pulmonary sarcoidosis. Preclinical studies showed no statistically significant impact on granuloma formation. The analysis estimated 65% probability of Phase III failure with projected 72% stock decline upon failure.
Beyond investment analysis, I conduct primary research into disease mechanisms and therapeutic approaches. My work on Alzheimer's disease proposes a novel perspective centered on the C/EBPβ-AEP pathway.
This paper presents a new perspective on Alzheimer's Disease, challenging mainstream hypotheses while leveraging existing research. The work proposes focusing on the C/EBPβ-AEP pathway, which could potentially improve both AD and PD pathologies. It suggests a combination therapy between a lead compound targeting this pathway and a ketogenic diet.
Read Paper →Following this research direction, I have pursued drugs and therapies with mechanisms of action similar to AEP inhibitors. This work was presented at the 25th Annual Biotech in Europe Forum in Basel in 2025, where partnership opportunities were explored.
Watch Presentation at Biotech in Europe Forum 2025For investment or acquisition discussions, strategic partnerships, or scientific collaboration, please reach out using the form below or through any of the channels listed.
Confidential materials can be shared under NDA.